About ac immune sa - ACIU
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.
ACIU At a Glance
AC Immune SA
EPFL Innovation Park
Lausanne, Vaud 1015
| Phone | 41-21-345-91-21 | Revenue | 4.30M | |
| Industry | Pharmaceuticals: Major | Net Income | -84,826,209.73 | |
| Sector | Health Technology | Employees | 122 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ACIU Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 73.533 |
| Price to Book Ratio | 5.639 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.583 |
| Enterprise Value to Sales | 48.046 |
| Total Debt to Enterprise Value | 0.028 |
ACIU Efficiency
| Revenue/Employee | 35,264.745 |
| Income Per Employee | -695,296.801 |
| Receivables Turnover | 5.005 |
| Total Asset Turnover | 0.019 |
ACIU Liquidity
| Current Ratio | 1.021 |
| Quick Ratio | 1.021 |
| Cash Ratio | 0.965 |
ACIU Profitability
| Gross Margin | N/A |
| Operating Margin | -1,929.947 |
| Pretax Margin | -1,971.648 |
| Net Margin | -1,971.648 |
| Return on Assets | -37.742 |
| Return on Equity | -93.97 |
| Return on Total Capital | -135.971 |
| Return on Invested Capital | -89.267 |
ACIU Capital Structure
| Total Debt to Total Equity | 10.117 |
| Total Debt to Total Capital | 9.188 |
| Total Debt to Total Assets | 2.944 |
| Long-Term Debt to Equity | 8.219 |
| Long-Term Debt to Total Capital | 7.464 |